Daily Respiratory Research Analysis
Analyzed 158 papers and selected 3 impactful papers.
Summary
Key advances today span transmission science, environmental epidemiology, and diagnostics. A human RSV challenge-modeling study pinpoints a narrow window of infectious shedding and dissects innate versus adaptive control. A Swedish high-exposure cohort links prenatal PFAS from contaminated water to increased childhood asthma. A de novo cell-free diagnostic platform achieves attomolar, preamplification-free detection of multiple respiratory viruses, enabling rapid point-of-care testing.
Research Themes
- Respiratory virus transmission dynamics and immune control
- Environmental toxicants and pediatric asthma risk
- Ultrasensitive point-of-care molecular diagnostics for respiratory pathogens
Selected Articles
1. Viral dynamics of the Respiratory Syncytial Virus during experimental human challenge: insights for transmission and protection.
In a 225-person RSV human challenge dataset, mechanistic modeling showed infectious virus is typically detectable from day 3 and clears by day 8 post-exposure, whereas RNA persists to ~12 days. Innate responses protect target cells and reduce production, while antibody-mediated responses accelerate clearance by ~3.5 days; paucisymptomatic cases contribute little to infectious shedding.
Impact: This study precisely quantifies the window of infectious shedding and disentangles innate versus adaptive contributions to viral control, informing isolation duration, test interpretation, and prophylaxis timing.
Clinical Implications: Isolation and testing strategies can target the ~5-day infectious shedding window post-exposure; RNA persistence beyond infectivity cautions against overinterpreting PCR positivity. Timing of monoclonal antibodies or vaccines can be aligned to early innate/adaptive kinetics.
Key Findings
- Infectious RSV detected ~3 days post-exposure and cleared by ~8 days; median infectious shedding window ~5 days.
- Viral RNA persists longer with median clearance ~12 days, outlasting infectious virus.
- Innate immunity reduces production/protects targets; non-antibody adaptive responses increased infected-cell loss ~7-fold; removing antibody effects delays clearance by ~3.5 days.
- Paucisymptomatic participants (~35% of cohort) contributed only ~5% of infectious shedding.
Methodological Strengths
- Large human challenge dataset (n=225) with integrated clinical, virologic, and immunologic measurements.
- Mechanistic modeling capturing innate and adaptive immune effects with prediction intervals.
Limitations
- Adult challenge participants may not represent children, elderly, or immunocompromised populations.
- Model assumptions and parameters may limit generalizability across RSV strains or co-infections.
Future Directions: Validate shedding windows and immune parameters across age groups and clinical infections; integrate mucosal immunity and variant effects; translate to optimized testing/isolation policies.
BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of respiratory infection. An in-depth quantification of its clinical, viral, and immune kinetics could provide further insights into tailoring interventions strategies at the individual and population levels. METHODS: We analyzed high-resolution viral, immunological and clinical data from 225 adults experimentally infected by RSV with mathematical models developed to characterize RSV host-pathogen interaction. RESULTS: The model providing the best fit to the data assumed three main mechanisms of action: a power-law relationship linking viral RNA to infectious virus, an innate immune response that protects target cells and reduces viral production, and an adaptive immune response integrating antibody-mediated and non-antibody-mediated components. The non-antibody-mediated response increased progressively the loss rate of infected cells by about 7-fold (90% Prediction Interval, PI: 2-20), whereas removal of the antibody-mediated response delayed infectious virus clearance by approximately 3.5 days. Infectious virus was detected 3 days post-exposure (dpe) (90% PI: 2-5 dpe), and cleared by 8 dpe (90% PI: 6-11 dpe), defining a median window of detectable infectious virus shedding of approximately 5 dpe (90% PI: 3.5-10 dpe). In contrast, viral RNA persisted longer, with a median clearance time of 12 days (90% PI: 9-15 dpe). Finally, the analysis of clinical evolution showed a significant association between the occurrence of symptoms and viral dynamics. While pauci-symptomatic individuals represented 35% of our population, they accounted for only ∼ 5% of infectious viral shedding. DISCUSSION: These results provide new insights into RSV infection to inform diagnostics, isolation and prevention strategies.
2. De novo-designed ribozyme-controlled riboregulator for cell-free diagnostics.
TRACKer is a modular, de novo cell-free diagnostic that couples ribozyme conformational switching with riboregulator-driven reporter cascades to detect respiratory viral RNAs at 1–10 aM without amplification in under 70 minutes. It supports both luminescent quantitation and lateral-flow readouts, enabling low-cost, scalable point-of-care deployment.
Impact: This platform overcomes a core constraint in molecular diagnostics—pre-amplification—while achieving attomolar sensitivity, offering a paradigm shift for rapid respiratory pathogen testing outside centralized labs.
Clinical Implications: Enables rapid, deployment-ready testing during outbreaks and routine care, with multiplex potential and flexible readouts to improve access, triage, and surveillance for respiratory infections.
Key Findings
- Ribozyme allostery plus riboregulator cascades enable preamplification-free detection with 1–10 aM sensitivity.
- Dual output modalities (luminescent quantitation and lateral flow) support laboratory and field use.
- Validated across six respiratory viruses with total assay time under 70 minutes.
Methodological Strengths
- De novo modular design integrating orthogonal biochemical control layers.
- Demonstrated ultra-high analytical sensitivity and two readout formats enabling broad deployment.
Limitations
- Lacks large-scale clinical validation across diverse specimen types and care settings.
- Manufacturing scale-up, assay robustness to inhibitors, and sample prep workflows require further evaluation.
Future Directions: Undertake multicenter clinical validation, expand multiplex panels, and integrate streamlined sample preparation for true point-of-care workflows.
Cell-free systems have great potential for nucleic acid assays, yet universal onsite diagnostics without preamplification are limited. Here, a universal cell-free diagnostic platform termed TRACKer (Target-Responsive non-preAmplification Cell-free diagnostic Kit) has been developed for detecting multiple respiratory viral RNAs in laboratory and field settings. TRACKer integrates three modules: ribozyme allostery module, riboregulator activation module, and output module. The ribozyme allostery module enables universal target recognition through strand displacement-mediated ribozyme conformational switching. The riboregulator activation module achieves preamplification-free detection via cascade expression of reporter proteins. The output module provides swappable reporter templates for luminescent quantification and lateral flow visualization in diverse scenarios. TRACKer is a robust system that enables rapid ( < 70 min) nucleic acid detection without preamplification and demonstrates attomolar sensitivity (1-10 aM) for six respiratory viruses. Overall, TRACKer presents a promising approach to nucleic acid detection, offering a low-cost and scalable solution with potential applications in point-of-care diagnostics and beyond.
3. Prenatal exposure to per- and polyfluoroalkyl substances (PFAS) and incidence of asthma and wheeze in childhood: A register-based cohort study in Ronneby, Sweden.
In a 11,488-child register-based cohort from a highly exposed Swedish municipality, very high prenatal PFAS exposure (AFFF-contaminated water) was associated with increased childhood asthma incidence (HR 1.44). Causal modeling corroborated higher cumulative asthma incidence in the very-high versus background exposure groups.
Impact: This study provides rare evidence from a high-exposure human population linking prenatal PFAS to incident childhood asthma, supporting regulatory actions and remediation priorities.
Clinical Implications: Clinicians in contaminated regions should consider PFAS exposure history when assessing pediatric respiratory risk and advocate for exposure mitigation; findings bolster population-level prevention strategies.
Key Findings
- In an open cohort of 11,488 children, very high prenatal PFAS exposure was associated with increased childhood asthma incidence (HR 1.44, 95% CI 1.08–1.92).
- Rubin Causal Model analysis estimated higher cumulative asthma incidence in very-high versus background exposure (26.7% vs 16.1%; p<0.001).
- No clear association was observed for wheeze or for intermediate/high (non-very-high) exposure categories.
Methodological Strengths
- Large population-based cohort with linkage of maternal residence to contaminated water distribution records.
- Adjusted Cox models and causal inference (RCM) with matched comparisons to mitigate confounding.
Limitations
- Exposure misclassification possible due to address-based proxy and inability to fully separate prenatal from early-life exposure.
- Outcome ascertainment via administrative records may miss milder or undiagnosed cases.
Future Directions: Replicate in other high-exposure settings with biomarker-based exposure assessment, disentangle prenatal versus postnatal windows, and explore mechanistic immune endpoints.
BACKGROUND: Early-life exposure to per- and polyfluoroalkyl substances (PFAS) may impact the developing lungs and immune system and increase the risk of childhood asthma, but no studies have been conducted in a high-exposed population. The objective of this study was to estimate associations between prenatal PFAS exposure and childhood incidence of asthma and wheeze in Blekinge County, Sweden, where a subset of residents in the city of Ronneby was exposed to PFAS from drinking water contaminated by aqueous film-forming foam (AFFF). METHODS AND FINDINGS: We constructed a register-based open cohort of 11,488 children born in Blekinge county between 2006 and 2013 and followed each individual from birth until age 12 or December 31, 2022. Maternal address history was linked to water distribution records to create a categorical proxy variable for prenatal PFAS exposure from drinking water. We identified incident cases of wheeze and asthma from administrative health records and estimated hazard ratios (HRs) using Cox proportional hazards models adjusted for individual-level confounders, including maternal smoking in early pregnancy, maternal age at delivery, parity, child sex, parental asthma, and socioeconomic factors. As a secondary analysis, we applied a Rubin Causal Model (RCM) analysis to estimate the average marginal effect of prenatal PFAS exposure on wheeze and asthma among the very highly-exposed population, using a matched dataset of very-high and background-exposed individuals balanced on measured confounders. Overall, 18% of children were diagnosed with wheeze and 17% with asthma during follow-up. Very high prenatal PFAS exposure was associated with incidence of asthma (HR: 1.44, 95% CI [1.08, 1.92]), whereas no associations were observed for the high or intermediate exposure groups or for wheeze. In the RCM analysis, the estimated cumulative incidence of asthma was 16.1% in the background-exposed group and 26.7% in the very highly exposed group (Fisherian p < 0.001). Study limitations include reliance on an address-based categorical proxy for prenatal PFAS exposure, which likely results in non-differential exposure misclassification and limits the ability to distinguish prenatal from early-childhood exposure effects. CONCLUSIONS: In this study, very high prenatal PFAS exposure was associated with a higher incidence of childhood asthma. Although these results should be replicated, they suggest an important public health impact of AFFF-associated PFAS contamination.